Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

671

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

February 29, 2016

Conditions
Dermatitis, Atopic
Interventions
DRUG

Dupilumab

Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms

DRUG

Placebo (for Dupilumab)

Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms

Trial Locations (101)

Unknown

Birmingham

Fort Smith

Rogers

Clovis

Lomita

Los Angeles

Oceanside

Palmdale

Rolling Hills Estates

San Diego

Santa Monica

Stockton

Boca Raton

Clearwater

Fort Lauderdale

Miami

Miami Lakes

Pensacola

Tampa

Newnan

Chicago

Normal

Evansville

Indianapolis

Louisville

Boston

Troy

St Louis

Newington

East Windsor

Buffalo

Corning

New Hyde Park

Rochester

High Point

Bethlehem

Upland

Chattanooga

Knoxville

San Antonio

Waco

Ogden

Newport News

Norfolk

Spokane

Dupnitsa

Plovdiv

Sofia

Winnepeg

Bathurst

Hamilton

Mississauga

Newmarket

Ottawa

Richmond Hill

Toronto

Copenhagen

Hellerup

Tallinn

Tartu

Helsinki

Tampere

Turku

Berlin

Bielefed

Blaubeuren Abbey

Erlangen

Halle

Hamburg

Hanover

München

Münster

Osnabrück

Schwerin

Stuttgart

Kurume

Fukuyama

Inashiki

Yokohama

Habikino

Neyagawa

Sakai

Takatsuki

Hamamatsu

Bunkyo-ku

Chuo-ku

Nerima-ku

Shinagawa

Shinjuku

Kofu

Gifu

Hiroshima

Kyoto

Osaka

Singapore

Alcañiz

Alicante

Barcelona

Madrid

Seville

Valencia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02277743 - Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter